UNASSIGNED:评估使用Ex-PRESS®植入物结合巩膜袋的改良方法在治疗遗传性转甲状腺素蛋白淀粉样变性(hATTR)继发性开角型青光眼中的有效性和安全性。
UNASSIGNED:这是一项回顾性分析。主要终点包括眼内压(IOP)评估(基线,第一天,第一周,1、3、6、12个月和最后一次随访)和降血压药物的数量(基线,6th,12个月和最后一次随访)。作为次要终点手术并发症,评估了是否需要额外的青光眼手术和LogMARBCVA.合格和完全成功定义为眼压从基线下降≥30%,有或没有额外的药物,分别。最短随访时间为12个月。
UNASSIGNED:共纳入32只眼,平均随访2.4±2.9年。眼压从基线(27.4±4.4mmHg)到第1天(5.00±2.9mmHg)显著下降,第一周(6.9±4.1mmHg),第1个月(11.7±7.8mmHg),第3个月(11.6±6.1mmHg),第6个月(13.1±6.8mmHg),第12个月(12.0±3.5mmHg)和最后一次就诊(11.8±2.4mmHg),p<0.001。与基线(3.8±0.6)和最后一次随访(0.4±0.8)相比,抗青光眼药物的数量也显着减少,p<0.001。LogMARBCVA保持稳定(基线为0.25±0.26,末次随访为0.25±0.24),p=0.767。17只眼出现短暂性低眼压(53.1%),但只有11人(34.4%)表现出前房变浅,需要额外护理,即睫状肌麻痹滴剂和粘弹性注射。22只眼(68.8%)的手术完全成功,6只眼(18.8%)的手术成功。四只眼睛(12.5%)需要额外的青光眼手术。
未经评估:改进的ExPRESS®技术似乎是有效的,特别是当需要低水平的IOP时。此外,需要较少的抗青光眼药物.另一方面,低张力是这个手术的常见副作用,尽管所有患者都得到了妥善处理,保留手术结果。
UNASSIGNED: To evaluate the effectiveness and safety of a modified approach using the Ex-PRESS® implant combined with a scleral pocket in the management of secondary open-angle glaucoma in hereditary transthyretin amyloidosis (
hATTR) at our department.
UNASSIGNED: This was a retrospective analysis. The primary endpoints included Intraocular pressure (IOP) evaluation (baseline, 1st day, 1st week, 1, 3, 6, 12 months and at last follow-up) and number of hypotensive drugs (baseline, 6th, 12th months and at last follow-up). As secondary endpoints surgical complications, the need for additional glaucoma surgery and LogMAR BCVA were evaluated. Qualified and complete success were defined as ≥ 30% IOP decrease from baseline, with or without additional medications, respectively. The minimum follow-up was 12 months.
UNASSIGNED: A total of 32 eyes were included with a mean follow-up of 2.4±2.9 years. IOP decreased significantly from baseline (27.4±4.4 mmHg) to 1st day (5.00±2.9 mmHg), 1st week (6.9±4.1 mmHg), 1st month (11.7±7.8 mmHg), 3rd month (11.6±6.1 mmHg), 6th month (13.1±6.8 mmHg), 12th month (12.0±3.5 mmHg) and last visit (11.8±2.4 mmHg), p<0.001. There was also a significant reduction in the number of antiglaucoma medications from baseline (3.8±0.6) and last follow-up (0.4±0.8), p<0.001. LogMAR BCVA remained stable (0.25±0.26 at baseline and 0.25±0.24 at last follow-up), p=0.767. Transient hypotony occurred in 17 eyes (53.1%), but only 11 (34.4%) exhibited anterior chamber shallowing and needed additional care, namely cycloplegic drops and viscoelastic injection. Complete surgical success was achieved in 22 eyes (68.8%) and qualified success in 6 eyes (18.8%). Four eyes (12.5%) needed additional glaucoma surgery.
UNASSIGNED: The modified ExPRESS® technique appears to be effective, especially when low levels of IOP are required. Additionally, fewer anti-glaucoma drugs were necessary. In the other hand, hypotony was a common side effect with this procedure, although all patients were properly handled, preserving the surgical outcomes.